Cargando…

Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist

BACKGROUND: There has been increased demand for greater public accountability and transparency of private sector-led global health partnership programs. This study critically reviews and pilot tests the World Health Organization (WHO) medicine program checklist as a framework for public reporting an...

Descripción completa

Detalles Bibliográficos
Autores principales: Umeh, Chukwuemeka A., Rockers, Peter C., Laing, Richard, Wagh, Ovi, Wirtz, Veronika J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098075/
https://www.ncbi.nlm.nih.gov/pubmed/32226630
http://dx.doi.org/10.1186/s40545-020-0204-z
_version_ 1783511114743545856
author Umeh, Chukwuemeka A.
Rockers, Peter C.
Laing, Richard
Wagh, Ovi
Wirtz, Veronika J.
author_facet Umeh, Chukwuemeka A.
Rockers, Peter C.
Laing, Richard
Wagh, Ovi
Wirtz, Veronika J.
author_sort Umeh, Chukwuemeka A.
collection PubMed
description BACKGROUND: There has been increased demand for greater public accountability and transparency of private sector-led global health partnership programs. This study critically reviews and pilot tests the World Health Organization (WHO) medicine program checklist as a framework for public reporting and assessing of programs. METHODS: We reviewed each question on the WHO checklist for clarity and usability. Next, we pilot tested the subset of checklist questions focused on program assessment. We extracted and analyzed publicly available information on one randomly selected program from each of the 20 largest research-based biopharmaceutical companies. For each program, we assessed whether publicly available information allowed for an assessment of each relevant question in the checklist. RESULTS: Checklist questions fit in four main categories: [1] national health and development plans, needs, capacity, laws and policies; [2] financial, performance, and public accountability; [3] risk management and mitigation strategies; and [4] long-term sustainability. Nearly all (21 of 22) questions in the checklist require information best provided by companies; one question requires information best provided by governments. Programs frequently reported on the public health needs of their programs (100%), program objectives and activities (100%) and the actual or expected program outputs (95%). There was less information on program alignment with country plans and capacity (50%), detailed program monitoring and evaluation plan (20%), risks mitigation strategies (5%), program needs assessment (5%), and additional resources required from or contributed by government (0%). CONCLUSION: The WHO checklist of key considerations for evaluating proposals for access to medicine programs could be a useful framework for public reporting of program information as most of checklist questions ask for data that should be available to those leading the program. Further revisions of the WHO checklist will help refine it to improve clarity and content validity.
format Online
Article
Text
id pubmed-7098075
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70980752020-03-27 Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist Umeh, Chukwuemeka A. Rockers, Peter C. Laing, Richard Wagh, Ovi Wirtz, Veronika J. J Pharm Policy Pract Research BACKGROUND: There has been increased demand for greater public accountability and transparency of private sector-led global health partnership programs. This study critically reviews and pilot tests the World Health Organization (WHO) medicine program checklist as a framework for public reporting and assessing of programs. METHODS: We reviewed each question on the WHO checklist for clarity and usability. Next, we pilot tested the subset of checklist questions focused on program assessment. We extracted and analyzed publicly available information on one randomly selected program from each of the 20 largest research-based biopharmaceutical companies. For each program, we assessed whether publicly available information allowed for an assessment of each relevant question in the checklist. RESULTS: Checklist questions fit in four main categories: [1] national health and development plans, needs, capacity, laws and policies; [2] financial, performance, and public accountability; [3] risk management and mitigation strategies; and [4] long-term sustainability. Nearly all (21 of 22) questions in the checklist require information best provided by companies; one question requires information best provided by governments. Programs frequently reported on the public health needs of their programs (100%), program objectives and activities (100%) and the actual or expected program outputs (95%). There was less information on program alignment with country plans and capacity (50%), detailed program monitoring and evaluation plan (20%), risks mitigation strategies (5%), program needs assessment (5%), and additional resources required from or contributed by government (0%). CONCLUSION: The WHO checklist of key considerations for evaluating proposals for access to medicine programs could be a useful framework for public reporting of program information as most of checklist questions ask for data that should be available to those leading the program. Further revisions of the WHO checklist will help refine it to improve clarity and content validity. BioMed Central 2020-03-26 /pmc/articles/PMC7098075/ /pubmed/32226630 http://dx.doi.org/10.1186/s40545-020-0204-z Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Umeh, Chukwuemeka A.
Rockers, Peter C.
Laing, Richard
Wagh, Ovi
Wirtz, Veronika J.
Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist
title Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist
title_full Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist
title_fullStr Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist
title_full_unstemmed Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist
title_short Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist
title_sort public reporting on pharmaceutical industry-led access programs: alignment with the who medicine programs evaluation checklist
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098075/
https://www.ncbi.nlm.nih.gov/pubmed/32226630
http://dx.doi.org/10.1186/s40545-020-0204-z
work_keys_str_mv AT umehchukwuemekaa publicreportingonpharmaceuticalindustryledaccessprogramsalignmentwiththewhomedicineprogramsevaluationchecklist
AT rockerspeterc publicreportingonpharmaceuticalindustryledaccessprogramsalignmentwiththewhomedicineprogramsevaluationchecklist
AT laingrichard publicreportingonpharmaceuticalindustryledaccessprogramsalignmentwiththewhomedicineprogramsevaluationchecklist
AT waghovi publicreportingonpharmaceuticalindustryledaccessprogramsalignmentwiththewhomedicineprogramsevaluationchecklist
AT wirtzveronikaj publicreportingonpharmaceuticalindustryledaccessprogramsalignmentwiththewhomedicineprogramsevaluationchecklist